Hemab Therapeutics
Clinical-stage biotechnology company developing prophylactic antibody therapies for underserved bleeding and thrombotic disorders, including rare conditions beyond hemophilia.
Notes
Hemab Therapeutics is a clinical-stage biotechnology company developing prophylactic antibody therapies for bleeding and thrombotic disorders. While much of the hemophilia market has been addressed by gene therapy and emicizumab, Hemab focuses on underserved patient populations including those with rare bleeding disorders and acquired conditions.
The company's lead program targets patients who cannot use existing therapies due to inhibitors or other complications. Hemab's approach uses novel antibody engineering to create therapies that work independently of traditional clotting factor pathways.
Hemab was founded in Copenhagen, Denmark and has attracted investment from leading European and U.S. life science investors.
Team
- Kristian Birch, M.D. - CEO
- LinkedIn: linkedin.com/in/kristianbirch
- Experienced team in hematology drug development
Additional Research Findings
- Founded in 2020, headquartered in Copenhagen, Denmark
- Portfolio company of Sofinnova Partners
- Clinical-stage development programs
- Focus on bleeding and thrombotic disorders
- Targeting underserved patient populations
- Antibody-based therapeutic approach
- Raised significant Series A/B funding
- European biotech with global development plans
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |